Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Trovagene sales and marketing update

    Trovagene Inc. (NASDAQ:TROV), San Diego, Calif. Business: Diagnostic Trovagene said Blue Cross Blue Shield (BCBS) of Illinois will cover Trovagenes Trovera liquid biopsy tests. The biotech markets Trovera EGFR, a non-…

    Published on 8/22/2016
  • Amgen sales and marketing update

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Cancer The U.K.s NICE issued a final appraisal determination (FAD) recommending Imlygic talimogene laherparepvec from Amgen to treat unresectable melanoma that …

    Published on 8/15/2016
  • Bioventus sales and marketing update

    Bioventus Inc., Durham, N.C. Business: Neurology Bioventus launched GELSYN-3 in the U.S. to treat pain associated with osteoarthritis of the knee. The wholesale acquisition cost (WAC) is $345 per 2 mL injection; one …

    Published on 8/15/2016
  • GlaxoSmithKline sales and marketing update

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Endocrine/Metabolic GlaxoSmithKline priced gene therapy Strimvelis (GSK2696273) at EUR594,000 ($663,679). In May, the European Commission approved …

    Published on 8/15/2016
  • LabCorp, Centers for Disease Control and Prevention sales and marketing update

    Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. U.S. Centers for Disease Control and Prevention, Atlanta, Ga. Business: Diagnostic LabCorp launched Zika MAC-ELISA developed by the CDC to diagnose Zika …

    Published on 8/15/2016
  • MDxHealth sales and marketing update

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Business: Diagnostic MDxHealth said Cigna Corp. (NYSE:CI, Bloomfield, Conn.) issued a positive medical policy decision for the biotechs ConfirmMDx for Prostate Cancer test.…

    Published on 8/15/2016
  • Shire sales and marketing update

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Cancer, Hematology The U.K.s NICE issued final draft guidance recommending Oncaspar pegaspargase from Shire as part of antineoplastic combination therapy to …

    Published on 8/15/2016
  • Takeda sales and marketing update

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Cancer The U.K.s NICE issued preliminary draft guidance recommending against the use of Takedas Adcetris brentuximab vedotin to treat CD30-positive …

    Published on 8/15/2016
  • Celgene sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Autoimmune The U.K.s NICE released draft guidance recommending the use of Otezla apremilast from Celgene to treat chronic plaque psoriasis. It recommended against the …

    Published on 8/8/2016
  • Cytox sales and marketing update

    Cytox Ltd., Birmingham, U.K. Business: Diagnostic Cytox launched its variaTECT SNP array genetic biomarker test and SNPfitR analysis software ito diagnose Alzheimers disease by determining amyloid positive patients from…

    Published on 8/8/2016
  • Great Basin Scientific sales and marketing update

    Great Basin Scientific Inc. (NASDAQ:GBSN), Salt Lake City, Utah Business: Diagnostic Great Basin launched its Shiga Toxin Direct Test in the U.S. to detect Shiga-producing strains of Escherichia coli as well as E. coli …

    Published on 8/8/2016
  • Keryx sales and marketing update

    Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), New York, N.Y. Business: Endocrine/Metabolic Keryx said it expects an imminent interruption in the supply of Auryxia ferric citrate that will disrupt patient access to the …

    Published on 8/8/2016
  • PTC sales and marketing update

    PTC Therapeutics Inc. (NASDAQ:PTCT), South Plainfield, N.J. Business: Musculoskeletal The U.K.s NICE issued final guidance recommending the use of Translarna ataluren from PTC to treat nonsense mutation Duchenne …

    Published on 8/8/2016
  • ANI Pharmaceuticals sales and marketing update

    ANI Pharmaceuticals Inc. (NASDAQ:ANIP), Baudette, Minn. Business: Generics, Cancer ANI launched a generic version of Nilandron nilutamide from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) in the U.S. The oral …

    Published on 8/1/2016
  • Bristol-Myers, Ono Pharmaceutical sales and marketing update

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Business: Cancer The U.K.s NICE issued final guidance recommending Opdivo nivolumab in combination with Yervoy …

    Published on 8/1/2016
  • Servier, Taiho sales and marketing update

    Servier, Neuilly-sur-Seine, France Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Business: Cancer The U.K.s NICE issued final draft guidance recommending Lonsurf trifluridine/tipiracil from Servier to treat metastatic …

    Published on 8/1/2016
  • UCB sales and marketing update

    UCB Group (Euronext:UCB), Brussels, Belgium Business: Autoimmune The U.K.s NICE issued draft guidance recommending Cimzia certolizumab pegol from UCB with or without methotrexate to treat severe rheumatoid arthritis (RA…

    Published on 8/1/2016
  • Bristol-Myers, Ono Pharmaceutical sales and marketing update

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Business: Cancer The U.K.s NICE issued draft guidance recommending against Opdivo nivolumab from Bristol-Myers …

    Published on 7/25/2016
  • Eli Lilly sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer The U.K.s NICE issued final draft guidance recommending Alimta pemetrexed from Eli Lilly as a maintenance treatment for locally advanced or metastatic …

    Published on 7/25/2016
  • United Therapeutics sales and marketing update

    United Therapeutics Corp. (NASDAQ:UTHR), Silver Spring, Md. Business: Cancer The U.K.s NICE issued final draft guidance recommending against Unituxin dinutuximab from United Therapeutics to treat high-risk neuroblastoma…

    Published on 7/25/2016
  • BioDelivery sales and marketing update

    BioDelivery Sciences International Inc. (NASDAQ: BDSI), Raleigh, N.C. Business: Neurology, Drug delivery BioDelivery said an undisclosed managed care plan made Bunavail buprenorphine/naloxone its preferred treatment for…

    Published on 7/18/2016
  • Bristol-Myers, Gilead sales and marketing update

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Massachusetts Medicaid agency MassHealth said it will make Gileads Harvoni ledipasvir/…

    Published on 7/18/2016
  • Citius Pharmaceuticals sales and marketing update

    Citius Pharmaceuticals Inc. (OTCQB:CTXR), Maynard, Mass. Business: Endocrine/Metabolic, Infectious, Gastrointestinal Citius said it will discontinue FDA-approved Suprenza phentermine orally disintegrating tablets to …

    Published on 7/18/2016
  • Ferring sales and marketing update

    Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland Business: Cancer The U.K.s NICE issued final draft guidance recommending the use of Firmagon degarelix from Ferring to treat advanced hormone-dependent prostate …

    Published on 7/18/2016
  • Celgene sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer The U.K.s NICE issued a final appraisal determination (FAD) recommending against the use of Vidaza azacitidine from Celgene to treat patients at least 65 years …

    Published on 7/11/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993